[go: up one dir, main page]

UA111470C2 - Спосіб отримання частинок зі зменшеними електростатичними зарядами - Google Patents

Спосіб отримання частинок зі зменшеними електростатичними зарядами

Info

Publication number
UA111470C2
UA111470C2 UAA201212060A UAA201212060A UA111470C2 UA 111470 C2 UA111470 C2 UA 111470C2 UA A201212060 A UAA201212060 A UA A201212060A UA A201212060 A UAA201212060 A UA A201212060A UA 111470 C2 UA111470 C2 UA 111470C2
Authority
UA
Ukraine
Prior art keywords
carrier particles
electrostatic charges
reduced electrostatic
preparing carrier
reduced
Prior art date
Application number
UAA201212060A
Other languages
English (en)
Russian (ru)
Inventor
Даніела Кокконі
Росселла МУЗА
Original Assignee
К'Єзі Фармачеутічі С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA111470(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by К'Єзі Фармачеутічі С.П.А. filed Critical К'Єзі Фармачеутічі С.П.А.
Publication of UA111470C2 publication Critical patent/UA111470C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Винахід стосується способу отримання частинок носія для препаратів у вигляді сухого порошку для інгаляції, що мають зменшені електростатичні заряди.
UAA201212060A 2010-04-21 2011-04-19 Спосіб отримання частинок зі зменшеними електростатичними зарядами UA111470C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160565 2010-04-21
PCT/EP2011/056227 WO2011131663A1 (en) 2010-04-21 2011-04-19 "process for providing particles with reduced electrostatic charges"

Publications (1)

Publication Number Publication Date
UA111470C2 true UA111470C2 (uk) 2016-05-10

Family

ID=42710544

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201212060A UA111470C2 (uk) 2010-04-21 2011-04-19 Спосіб отримання частинок зі зменшеними електростатичними зарядами

Country Status (26)

Country Link
US (3) US20110262543A1 (uk)
EP (1) EP2560611B1 (uk)
JP (1) JP5913289B2 (uk)
KR (2) KR20130062268A (uk)
CN (1) CN102858320B (uk)
AR (1) AR081540A1 (uk)
AU (1) AU2011244384B2 (uk)
BR (1) BR112012026804B1 (uk)
CA (1) CA2796934C (uk)
DK (1) DK2560611T3 (uk)
ES (1) ES2658179T3 (uk)
HR (1) HRP20180488T1 (uk)
HU (1) HUE038555T2 (uk)
IL (1) IL222519B (uk)
MX (1) MX2012012045A (uk)
MY (1) MY163011A (uk)
NO (1) NO2560611T3 (uk)
PH (1) PH12012501988B1 (uk)
PL (1) PL2560611T3 (uk)
PT (1) PT2560611T (uk)
RU (1) RU2580312C2 (uk)
SG (1) SG184964A1 (uk)
SI (1) SI2560611T1 (uk)
TW (1) TWI530301B (uk)
UA (1) UA111470C2 (uk)
WO (1) WO2011131663A1 (uk)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013142268A (ru) * 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
WO2013109209A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising fluticasone
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
WO2013109211A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
FI3412277T3 (fi) * 2012-01-25 2023-03-23 Chiesi Farm Spa Kortikosteroidia ja beeta-adrenergista ainetta käsittävä kuivajauheformulaatio annettavaksi inhalaatiolla
GB201205632D0 (en) * 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
ES2814336T3 (es) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
WO2014106727A1 (en) * 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
PT3019153T (pt) * 2013-07-11 2018-12-04 Chiesi Farm Spa Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
ES2793905T3 (es) 2014-09-09 2020-11-17 Vectura Ltd Formulación que comprende glicopirrolato, método y aparato
HRP20200571T1 (hr) 2015-11-16 2020-07-10 Chiesi Farmaceutici S.P.A. Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik
CN105891616B (zh) * 2016-06-15 2018-06-15 北京航空航天大学 一种研究带电颗粒与火焰相互作用的实验装置
WO2018018669A1 (en) * 2016-07-28 2018-02-01 Esd Technology Consulting & Licensing Co., Ltd. Static charge reduction system
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
EP3910324A1 (en) 2018-08-07 2021-11-17 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
WO2021058454A1 (en) 2019-09-24 2021-04-01 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
IL300652A (en) 2020-08-14 2023-04-01 Norton Waterford Ltd Inhalable formulation of fluticasone propionate and albuterol sulfate
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
EP4452223A1 (en) 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN115400103B (zh) * 2022-09-22 2023-11-24 苏州易合医药有限公司 一种多孔性呼吸颗粒及其制备方法
CA3268243A1 (en) 2022-09-22 2024-03-28 Chiesi Farm Spa CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
CN115770221A (zh) * 2022-12-29 2023-03-10 浙江上药九旭药业有限公司 银杏酮酯粉体、银杏酮酯滴丸剂及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
ATE284677T1 (de) * 1997-03-20 2005-01-15 Schering Corp Herstellung von pulveragglomeraten
DK1131059T3 (da) 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
DK1296651T3 (da) * 2000-06-27 2008-02-11 Vectura Ltd Fremgangsmåde til fremstilling af partikler til anvendelse i et farmaceutisk præparat
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
DE60239639D1 (de) 2002-07-31 2011-05-12 Chiesi Farma Spa Pulverinhalator
WO2005004845A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
ES2909080T3 (es) 2004-04-23 2022-05-05 Cydex Pharmaceuticals Inc Formulación de DPI que contiene sulfoalquil éter ciclodextrina
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
CN101490004B (zh) 2006-07-14 2012-01-11 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烯基醇的衍生物
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof

Also Published As

Publication number Publication date
CN102858320A (zh) 2013-01-02
CA2796934A1 (en) 2011-10-27
BR112012026804A2 (pt) 2016-07-12
KR101863523B1 (ko) 2018-05-31
CN102858320B (zh) 2014-10-29
CA2796934C (en) 2018-11-20
HUE038555T2 (hu) 2018-10-29
PT2560611T (pt) 2018-02-07
SG184964A1 (en) 2012-11-29
DK2560611T3 (en) 2018-02-26
US20230364015A1 (en) 2023-11-16
JP2013525327A (ja) 2013-06-20
RU2580312C2 (ru) 2016-04-10
HK1174570A1 (en) 2013-06-14
WO2011131663A1 (en) 2011-10-27
EP2560611B1 (en) 2018-01-03
JP5913289B2 (ja) 2016-04-27
TW201206498A (en) 2012-02-16
KR20130062268A (ko) 2013-06-12
PH12012501988B1 (en) 2018-03-07
HRP20180488T1 (hr) 2018-07-13
AR081540A1 (es) 2012-10-03
PH12012501988A1 (en) 2013-04-14
IL222519B (en) 2018-03-29
MX2012012045A (es) 2012-12-17
BR112012026804B1 (pt) 2021-11-16
IL222519A0 (en) 2012-12-31
NO2560611T3 (uk) 2018-06-02
ES2658179T3 (es) 2018-03-08
AU2011244384A1 (en) 2012-11-15
US20110262543A1 (en) 2011-10-27
KR20170118975A (ko) 2017-10-25
SI2560611T1 (en) 2018-03-30
AU2011244384B2 (en) 2016-06-23
TWI530301B (zh) 2016-04-21
PL2560611T3 (pl) 2018-05-30
RU2012145762A (ru) 2014-05-27
EP2560611A1 (en) 2013-02-27
US20190216731A1 (en) 2019-07-18
MY163011A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
UA111470C2 (uk) Спосіб отримання частинок зі зменшеними електростатичними зарядами
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
SG184352A1 (en) Process for preparing carrier particles for dry powders for inhalation
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
GB201103836D0 (en) Conjugation process
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
ZA201103820B (en) Process for the preparation of tenofovir
IN2015DN01061A (uk)
MY168300A (en) Pharmaceutical Composition for Inhalation
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
ZA201501372B (en) Production of soluble protein products from hemp ("h701")
PH12013501859A1 (en) Indolecarboxamides and benzimidazolecarboxamides as insecticides and acaricides
TR201906966T4 (tr) Hibrit karbon siyahı parçacıklarının imalatı için yöntem ve tertibat.
MY156843A (en) Silver powder and method for producing same
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IN2014DN06964A (uk)
PH12013501708B1 (en) Commercial scale process for production of prrsv
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
WO2013046233A3 (en) Process for the preparation of octreotide acetate
HUE037625T2 (hu) Eljárás tûzoltó porok visszanyerésére
IL235428A0 (en) A process for the preparation of cyclic endopeptides